Five-Year Actuarial Estimate of Disease-Free Survival and Cumulative Incidences of Relapse and Nonrelapse Mortality and Univariate P for Patients With Previously Untreated Secondary AML
Patient Category . | No. . | Disease-Free Survival . | Relapse . | Nonrelapse Mortality . | |||
---|---|---|---|---|---|---|---|
. | . | % . | P . | % . | P . | % . | P . |
All untreated patients | 46 | 24.4 | 31.3 | 44.3 | |||
Discrete variables: | |||||||
PB blasts at SCT3-150 | |||||||
0-3.0 (×109 cells/L) | 16 | 31.3 | 18.8 | 50.0 | |||
3.1-5.5 (×109 cells/L) | 15 | 32.0 | .676 | 21.3 | .919 | 46.7 | .667 |
>5.5 (×109 cells/L) | 15 | 20.0 | .224 | 53.3 | .034 | 46.7 | .702 |
Disease etiology | |||||||
MDS-related | 29 | 34.5 | 24.1 | 41.4 | |||
Therapy-related | 17 | 7.8 | .159 | 43.1 | .160 | 49.0 | .516 |
Patient age | |||||||
<40 yrs | 22 | 31.8 | 36.4 | 31.8 | |||
≥40 yrs | 24 | 14.6 | .335 | 28.1 | .780 | 57.3 | .142 |
Donor | |||||||
Genotypic match | 30 | 27.5 | 31.3 | 41.3 | |||
Nongenotypic match | 16 | 18.8 | .432 | 31.3 | .728 | 50.0 | .464 |
Preparative regimen | |||||||
Chemo only or Cy + ≤14.4 Gy TBI3-151 | 28 | 19.1 | 40.5 | 40.5 | |||
15.75 Gy TBI or Bu-Cy-TBI3-152 | 18 | 33.3 | .382 | 16.7 | .116 | 50.0 | .817 |
Continuous variables: | |||||||
Peripheral blood blasts at SCT | .111 | .050 | .677 | ||||
Patient age | .152 | .802 | .096 | ||||
Disease duration | .137 | .352 | .245 | ||||
Time from MDS diagnosis to AML diagnosis | .212 | .374 | .371 | ||||
Time from AML diagnosis to SCT | .026 | .659 | .020 | ||||
Hematocrit at time of SCT | .415 | .525 | .593 | ||||
Neutrophil count at time of SCT | .087 | .045 | .607 | ||||
Platelet count at time of SCT | .104 | .320 | .198 |
Patient Category . | No. . | Disease-Free Survival . | Relapse . | Nonrelapse Mortality . | |||
---|---|---|---|---|---|---|---|
. | . | % . | P . | % . | P . | % . | P . |
All untreated patients | 46 | 24.4 | 31.3 | 44.3 | |||
Discrete variables: | |||||||
PB blasts at SCT3-150 | |||||||
0-3.0 (×109 cells/L) | 16 | 31.3 | 18.8 | 50.0 | |||
3.1-5.5 (×109 cells/L) | 15 | 32.0 | .676 | 21.3 | .919 | 46.7 | .667 |
>5.5 (×109 cells/L) | 15 | 20.0 | .224 | 53.3 | .034 | 46.7 | .702 |
Disease etiology | |||||||
MDS-related | 29 | 34.5 | 24.1 | 41.4 | |||
Therapy-related | 17 | 7.8 | .159 | 43.1 | .160 | 49.0 | .516 |
Patient age | |||||||
<40 yrs | 22 | 31.8 | 36.4 | 31.8 | |||
≥40 yrs | 24 | 14.6 | .335 | 28.1 | .780 | 57.3 | .142 |
Donor | |||||||
Genotypic match | 30 | 27.5 | 31.3 | 41.3 | |||
Nongenotypic match | 16 | 18.8 | .432 | 31.3 | .728 | 50.0 | .464 |
Preparative regimen | |||||||
Chemo only or Cy + ≤14.4 Gy TBI3-151 | 28 | 19.1 | 40.5 | 40.5 | |||
15.75 Gy TBI or Bu-Cy-TBI3-152 | 18 | 33.3 | .382 | 16.7 | .116 | 50.0 | .817 |
Continuous variables: | |||||||
Peripheral blood blasts at SCT | .111 | .050 | .677 | ||||
Patient age | .152 | .802 | .096 | ||||
Disease duration | .137 | .352 | .245 | ||||
Time from MDS diagnosis to AML diagnosis | .212 | .374 | .371 | ||||
Time from AML diagnosis to SCT | .026 | .659 | .020 | ||||
Hematocrit at time of SCT | .415 | .525 | .593 | ||||
Neutrophil count at time of SCT | .087 | .045 | .607 | ||||
Platelet count at time of SCT | .104 | .320 | .198 |